Table 3.
Association of anti-spike IgG with disease characteristics
| Type of malignancy | Positive anti-SARS-CoV-2 spike IgG patients, n (%) | Negative anti-SARS-CoV-2 spike IgG patients, n (%) | p value |
|---|---|---|---|
| Solid malignancy | 131 (98%) | 3 (2%) | 0.001053∗ |
| Hematologic malignancy | 56 (85%) | 10 (15%) | |
| Type of cancer therapy | |||
| Anti-CD20 | 16 (70%) | 7 (30%) | 0.0001168∗∗ |
| Stem cell transplant | 19 (73%) | 7 (27%) | 0.0002866∗∗ |
| CAR-T cell therapy | 0 (0%) | 3 (100%) | 0.0002178∗∗ |
| Hormonal therapy | 47 (100%) | 0 (0%) | 0.04129∗∗ |
| Immune checkpoint inhibitor therapy | 30 (97%) | 1 (3%) | 0.6962 |
∗Statistically significant when compared with each other.
∗∗Statistically significant when compared with overall cohort.